File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S1473-3099(09)70056-8
- Scopus: eid_2-s2.0-62549089691
- PMID: 19324298
- WOS: WOS:000264629500020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Prevention and management of drug resistance for antihepatitis B treatment
Title | Prevention and management of drug resistance for antihepatitis B treatment |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetid |
Citation | The Lancet Infectious Diseases, 2009, v. 9 n. 4, p. 256-264 How to Cite? |
Abstract | Emergence of drug resistance in antiviral therapy for chronic hepatitis B negates treatment benefits. There is a lower chance for emergence of resistance for drugs with rapid and potent viral suppression and a high genetic barrier for resistant mutations. Measurement of viral load at 24 weeks' treatment to aid decision making is mandatory for patients receiving drugs that are associated with a higher resistance rate. Combination treatment with drugs that belong to different groups is associated with a lower chance of resistance. To ensure better control of viral replication in patients with drug resistance, the addition of another drug without an overlapping resistance profile should be given as early as possible, preferably at the time when genotypic resistance emerges. With such strategies, most patients can be maintained in clinical remission. However, because of the mechanism of viral persistence, research efforts should continue to anticipate and prevent the emergence of multidrug-resistant strains. © 2009 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/163236 |
ISSN | 2021 Impact Factor: 71.421 2020 SCImago Journal Rankings: 7.475 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yuen, MF | en_US |
dc.contributor.author | Fung, J | en_US |
dc.contributor.author | Wong, DKH | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.date.accessioned | 2012-09-05T05:29:02Z | - |
dc.date.available | 2012-09-05T05:29:02Z | - |
dc.date.issued | 2009 | en_US |
dc.identifier.citation | The Lancet Infectious Diseases, 2009, v. 9 n. 4, p. 256-264 | en_US |
dc.identifier.issn | 1473-3099 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163236 | - |
dc.description.abstract | Emergence of drug resistance in antiviral therapy for chronic hepatitis B negates treatment benefits. There is a lower chance for emergence of resistance for drugs with rapid and potent viral suppression and a high genetic barrier for resistant mutations. Measurement of viral load at 24 weeks' treatment to aid decision making is mandatory for patients receiving drugs that are associated with a higher resistance rate. Combination treatment with drugs that belong to different groups is associated with a lower chance of resistance. To ensure better control of viral replication in patients with drug resistance, the addition of another drug without an overlapping resistance profile should be given as early as possible, preferably at the time when genotypic resistance emerges. With such strategies, most patients can be maintained in clinical remission. However, because of the mechanism of viral persistence, research efforts should continue to anticipate and prevent the emergence of multidrug-resistant strains. © 2009 Elsevier Ltd. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | The Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetid | en_US |
dc.relation.ispartof | The Lancet Infectious Diseases | en_US |
dc.subject.mesh | Antiviral Agents - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Drug Resistance, Viral - Genetics | en_US |
dc.subject.mesh | Hepatitis B Virus - Drug Effects - Genetics | en_US |
dc.subject.mesh | Hepatitis B, Chronic - Drug Therapy - Virology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Mutation | en_US |
dc.subject.mesh | Viral Load | en_US |
dc.title | Prevention and management of drug resistance for antihepatitis B treatment | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yuen, MF:mfyuen@hkucc.hku.hk | en_US |
dc.identifier.email | Fung, J:jfung@sicklehut.com | en_US |
dc.identifier.email | Wong, DKH:danywong@hku.hk | en_US |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_US |
dc.identifier.authority | Yuen, MF=rp00479 | en_US |
dc.identifier.authority | Fung, J=rp00518 | en_US |
dc.identifier.authority | Wong, DKH=rp00492 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S1473-3099(09)70056-8 | en_US |
dc.identifier.pmid | 19324298 | - |
dc.identifier.scopus | eid_2-s2.0-62549089691 | en_US |
dc.identifier.hkuros | 161051 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-62549089691&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.spage | 256 | en_US |
dc.identifier.epage | 264 | en_US |
dc.identifier.eissn | 1474-4457 | - |
dc.identifier.isi | WOS:000264629500020 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Yuen, MF=7102031955 | en_US |
dc.identifier.scopusauthorid | Fung, J=23091109300 | en_US |
dc.identifier.scopusauthorid | Wong, DKH=7401535819 | en_US |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_US |
dc.identifier.issnl | 1473-3099 | - |